UPDATE: Novo Nordisk’s CEO, Mike Doustdar, has issued a stark warning regarding the dangers of compounded GLP-1 drugs as a legal battle intensifies. He claims that knockoff medications, particularly those sourced from overseas, could jeopardize patient safety and undermine FDA oversight. This urgent issue is gaining traction as the company confronts Hims & Hers Health in court, alleging the sale of unapproved, compounded versions of its medications.
During an appearance on FOX Business with Maria Bartiromo, Doustdar criticized the “mass compounding” practices of telehealth firms, stating, “When you go and try to source raw materials from China or unknown sources… there is something wrong with this.” This escalating concern highlights the potential risks posed by these copycat drugs, which have surged in availability as patients seek alternatives to brand-name treatments.
Hims & Hers has responded to Novo’s lawsuit, describing it as a “blatant attack” on millions of Americans who rely on compounded medications for personalized healthcare. The company asserts that this legal move restricts consumer choice and undermines a critical aspect of U.S. pharmacy practice.
“This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of U.S. pharmacy practice,” a representative stated.
Doustdar emphasized that compounded drugs are typically intended for individual patients with specific needs, not for mass production. “Compounding is supposed to be for a few individuals that have, let’s say, allergic reactions to the real medicine,” he remarked. He further expressed alarm over Hims & Hers’ introduction of a compounded oral semaglutide, which was briefly marketed at $49 per month, significantly undercutting Novo’s FDA-approved oral Wegovy, priced at approximately $149 and potentially up to $299 at higher doses.
The legal dispute reflects larger concerns surrounding the rise of “gray-market” weight-loss drugs flooding the U.S. market, prompting experts to warn about potential health risks. Doustdar stated that Novo’s recent pricing adjustments have made such knockoffs unnecessary, as the cost of branded medications has become more competitive.
As the legal battle unfolds, patients seeking GLP-1 therapy for obesity, type 2 diabetes, and other metabolic conditions are left in a precarious position. With Novo’s efforts to combat the rise of compounded versions, the future of these weight-loss drugs and their accessibility remains uncertain.
Watch for further developments in this urgent situation as both companies prepare to face off in court, with implications that could affect the healthcare landscape for countless patients across the nation.
